4ª Edição

Presented on ASCO plenum, the JUPITER-02 research achieved promising results for nasopharyngeal carcinoma

per: Grupo Oncoclínicas
Presented on ASCO plenum, the JUPITER-02 research achieved promising results for nasopharyngeal carcinoma

Scientific commission

Marcelo Salgado
Marcelo Salgado
Pedro de Marchi
Pedro de Marchi

Contributors

Cristiano Guedes
Cristiano Guedes
João Paulo Vasconcelos
João Paulo Vasconcelos

New immunotherapy agent toripalimab demonstrated positive outcome regarding progression-free survival, rate and duration of response when associated with conventional chemotherapy in nasopharyngeal carcinoma treatment.

In this context, the findings of phase III JUPITER-02 research with toripalimab were presented, during the ASCO 2021 higher importance plenum. “It’s the first study to highlight unequivocal benefit of an immunotherapy agent on metastatic nasopharyngeal carcinoma first line treatment”, says oncologist João Paulo Vasconcelos, from Belo Horizonte Oncocentro, part of the Oncoclinicas Group.

According to Cristiano Guedes, oncologist from Rio de Janeiro Oncoclinicas, it’s vital to highlight that a patient with recurring or oligometastatic illness should be, first and foremost, evaluated by a multidisciplinary team. “Once the possibility of locoregional therapy, such as surgery or re-radiation, is discarded, systemic treatment is advised. Preferential treatment consists of using cisplatin and gemcitabine. Other composite options might be considered, such as carboplatin and gemcitabine, platinum (carboplatin or cisplatin) partnered with paclitaxel or docetaxel. Single agents, such as platinum, taxanes, methotrexate or capecitabine, may also be used.”

To read the full article with all research details, access our website.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L